The efficacy of pegfilgrastim±chemotherapy for mobilizing stem cells in patients with solid tumours was assessed. In cycle 0, a 14-day prechemotherapy cycle, patients (N ¼ 61) were randomized open-label to single doses of pegfilgrastim (6, 12 or 18 mg) on day 1, or daily filgrastim (10 lg/kg) for p7 days. Mean peak peripheral CD34 þ cell counts increased with pegfilgrastim dose, but were significantly higher than filgrastim only at the 18 mg dose (10.17 vs 4.96 Â 10 4 /ml; P ¼ 0.014). In the clinically relevant period of days 3-7, both 12 and 18 mg pegfilgrastim doses produced significantly higher peak CD34 þ counts (8.18 and 9.96 vs 4.51 Â 10 4 /ml for filgrastim; P ¼ 0.034 and 0.006). In cycle 1, patients received carboplatin/paclitaxel on day 1, followed from day 2 by pegfilgrastim 6-18 mg or daily filgrastim (5 lg/ kg/day for p14 days) as per randomization in cycle 0. There were no significant differences in mean peak CD34 þ count between pegfilgrastim and filgrastim, but there was an advantage for pegfilgrastim 18 mg in the relevant period of days 7-12 (3.14 vs 1.19 Â 10 4 /ml; P ¼ 0.043). A single pegfilgrastim dose (X6 mg) could be substituted for daily filgrastim in cytokine-only peripheral CD34 þ cell mobilization.
Introduction
High-dose myeloablative chemotherapy followed by autologous PBPC infusion is routinely used in high-risk and relapsed malignant diseases. [1] [2] [3] PBPC mobilization is routinely achieved through the administration of cytokines, particularly G-CSF (for example, filgrastim), alone or in conjunction with myelosuppressive chemotherapy. 1, 4 Pegfilgrastim is a polyethylene glycol-filgrastim conjugate with neutrophil-mediated pharmacokinetics and a sustained duration of action, allowing several daily injections of filgrastim to be replaced by a single injection of pegfilgrastim. [5] [6] [7] The non-inferiority of single-dose pegfilgrastim (6 mg) to daily filgrastim (5 mg/kg) in the treatment of chemotherapy-induced neutropenia has been shown in two phase III clinical trials in patients with breast cancer, [8] [9] [10] a pegfilgrastim dose-finding study in women with breast cancer, 11 two open-label studies in patients with lymphoma, 12, 13 children with Ewing's sarcoma 14 and in a retrospective analysis of patients with various haematological malignancies. 15 Following PBPC mobilization, the number of CD34 þ cells in the leukapheresis product is predictive of engraftment success and subsequent haematopoietic recovery. 1, 2 Successful mobilization of CD34 þ cells with single-dose pegfilgrastim (30-300 mg/kg) has been shown in healthy human volunteers 7 and non-small cell lung cancer patients. 16 Single fixed 6 and 12 mg doses of pegfilgrastim have been reported to mobilize CD34 þ cells in patients with lymphoma or multiple myeloma. 17, 18 A correlation has been noted between CD34 þ -cell mobilization and progenitor-cell mobilization in response to pegfilgrastim in healthy human volunteers 7 and non-small cell lung cancer patients, both pre and postchemotherapy. 19 There has been little systematic investigation of the ability of fixed doses of pegfilgrastim pre and postchemotherapy to mobilize CD34 þ cells and progenitor cells in cancer patients. The purpose of this study was to provide preliminary data on the optimal fixed dose of pegfilgrastim for CD34
þ and progenitor cell mobilization in patients with solid tumours, when given alone or combined with chemotherapy.
Patients and methods

Patient population Between August 2002 and April 2004, patients between 18
and 65 years of age, with a pathologically confirmed diagnosis of a solid tumour suitable for treatment with intensified carboplatin and paclitaxel, who had not received prior chemotherapy or radiotherapy, were evaluated for enrollment in this randomized open-label study conducted at six centres in the United Kingdom. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, inclusive; life expectancy with treatment X12 weeks; an ANC 42.0 Â 10 9 /l; plt count 4100 Â 10 9 /l; glomerular filtration rate X60 ml/min; total serum bilirubin less than two times the upper limit of normal. Key exclusion criteria included previous malignancy within the preceding 5 years, with the exception of surgically cured basal or squamous skin cell carcinoma or carcinoma of the cervix in situ; presence of a premalignant myeloid condition; previous exposure to pegfilgrastim; known sensitivity to products derived from Escherichia coli.
Study design and treatment
The study (Clinicaltrials.gov: NCT00117442) comprised a 14-day prechemotherapy cycle (cycle 0), immediately followed by a 21-day carboplatin/paclitaxel chemotherapy cycle (cycle 1; Figure 1 ). Patients were randomized in a 1:1:1:1 ratio to receive a fixed dose of 6, 12 or 18 mg of pegfilgrastim (one, two or three injections of pegfilgrastim 6 mg (Neulasta, Amgen Inc., Thousand Oaks, CA, USA)) on day 1 of cycle 0, or daily doses of filgrastim (10 mg/kg) (Neupogen, Amgen Inc., Thousand Oaks, CA, USA) from day 1 of the cycle until day 7, or until an ANC X75 Â 10 9 /l, whichever occurred first. On day 2 of the immediately subsequent cycle 1, approximately 24 h after receiving carboplatin area under the curve (AUC) ¼ 6; 1 h i.v. infusion) and paclitaxel (175 mg/m 2 ; 3 h i.v. infusion), patients received either a single dose of pegfilgrastim at the same dose as in cycle 0, or the first of a series of daily doses of filgrastim (5 mg/kg) that continued until an ANC X10 Â 10 9 /l or for a maximum of 14 days, whichever occurred first.
Investigators were permitted to prescribe any concomitant medications considered necessary for adequate supportive care, with the exception of any other investigational agent or haematopoietic growth factor (other than erythropoietin for the treatment of anaemia), corticosteroids (except topical steroids, inhaled steroids, chemotherapy premedications or for the treatment of an adverse event), radiotherapy and WBC transfusions.
This study was performed in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committee of each participating institution, and written informed consent was obtained from all patients before the performance of any study-related procedure.
Study end points CD34
þ cells, mononuclear cells and colony-forming progenitor cells were quantified in blood samples collected daily from day 1 to day 7, and on days 9 and 12 during cycle 0, and on days 1 and 3, daily from day 7 to day 12 and on days 15 and 18 during cycle 1.
The primary end point was the peak peripheral CD34 /ml for 42 consecutive measurements during cycles 0 and 1, and at any time during cycles 0 and 1.
Blood samples for complete blood counts were collected at the same time as the samples for CD34 þ cell determinations, and blood chemistry evaluations were performed on day 1 of each cycle (before the administration of chemotherapy in cycle 1).
Glomerular filtration rate was calculated from the serum creatinine level on day 1 of each cycle (before the administration of chemotherapy in cycle 1) using the Cockroft-Gault equation. 20 Adverse events were recorded from the first day of cytokine administration.
Statistical analysis
On the basis of previous experience, it was calculated that a sample size of 15 patients in each treatment group would provide 95% confidence intervals of width (22 and 152%) for increases of 75% in mean peak (maximum) peripheral CD34 þ cell counts between consecutive pegfilgrastim treatment groups, requiring a total of 60 patients to be enroled in the study. It was similarly calculated that the study would provide approximately 80% power that a difference between the groups would be detected using analysis of variance, assuming a linear dose effect for pegfilgrastim with an assumed difference between consecutive pegfilgrastim groups of 75%.
Analyses were conducted primarily in terms of descriptive summary statistics. Data were log transformed before analysis as they were highly positively skewed. Two-sided 95% confidence intervals for treatment group differences were calculated, and pair-wise comparisons between the pegfilgrastim and filgrastim groups were made as appropriate. No adjustment was made for multiple comparisons.
Efficacy analyses were performed on the full analysis set, which comprised all randomized patients who received at least one dose of pegfilgrastim or filgrastim, and data were analysed according to the treatment assigned, irrespective of the actual treatment received. The safety analysis set also comprised all the patients who received at least one dose of pegfilgrastim or filgrastim, and data were analysed in relation to the cytokine received, irrespective of randomization allocation.
Results
A total of 61 patients were enroled in the study, all of whom received at least one dose of pegfilgrastim or filgrastim. Sixteen patients were randomized to receive pegfilgrastim 6 mg, whereas 15 patients were randomized to each of the other three treatment groups. Demographic data are shown in Table 1 .
In total, 53 patients completed cycles 0 and 1. Reasons for withdrawal were adverse events (pegfilgrastim 6 mg N ¼ 2, pegfilgrastim 18 mg N ¼ 1), death (pegfilgrastim 6 mg N ¼ 1, pegfilgrastim 12 mg N ¼ 1), non-compliance Table 1 Characteristics of the randomized patients 
Peripheral CD34
þ cell counts in cycle 0 Mean peripheral CD34 þ cell profiles over time in cycle 0 are shown in Figure 2 . The mean peak peripheral CD34 þ cell counts in each treatment group are detailed in Table 2 . The timing of mobilization in each treatment group was comparable. The peak peripheral CD34 þ cell counts were observed between days 4 and 6 for 85% of patients overall. Mobilization of CD34 þ cells was similar in the pegfilgrastim 6 mg group and the filgrastim 10 mg/kg/day group. Dose-dependent increases were seen with the pegfilgrastim 12 and 18 mg doses, reaching statistical significance in the patients receiving the highest dose. The mean peak peripheral CD34 þ cell count was significantly higher in the pegfilgrastim 18 mg group than in the filgrastim group (10.17 Â 10 4 /ml vs 4.96 Â 10 4 /ml, respectively; P ¼ 0.014). An identical analysis was performed in relation only to days 3-7 of cycle 0, a period based on the clinical experience of peak mobilization response to cytokines in the absence of chemotherapy, and in which peak peripheral CD34 þ cell counts were observed for 95% of patients in this study. In this analysis, the difference in mean peak peripheral CD34
þ cell count between patients receiving a 12-mg dose of pegfilgrastim and patients receiving filgrastim was also statistically significant (8. /ml for greater than two consecutive measurements than did the patients in the 6 mg pegfilgrastim and filgrastim treatment groups (53 and 80% vs 13 and 33%, respectively).
þ cell counts in cycle 1 The mean peak peripheral CD34 þ cell counts in each treatment group are detailed in Table 3 . In all treatment groups, peripheral CD34 þ cell counts were lower than anticipated. In both the 6 and 12 mg pegfilgrastim treatment groups, the mean peak peripheral CD34 þ cell count was similar to that for patients in the filgrastim group. A slightly higher mean value was obtained for patients in the 18 mg pegfilgrastim group, but this was not statistically significantly different from that in the filgrastim group.
The timing of mobilization in each treatment group was comparable. The peak peripheral CD34 þ cell counts were observed between days 7 and 12 for the majority of patients (38/58; 66%). However, for 4/15 (27%) patients in the 6 mg pegfilgrastim group, 2/14 (14%) patients in the 12 mg pegfilgrastim group and 4/14 (29%) patients in the filgrastim group, peak counts occurred on day 3 of the cycle. In addition, three (5%) of the 58 patients who started cycle 1 (one in the 6 mg pegfilgrastim group and two in the 18 mg pegfilgrastim group) withdrew from the study having provided only one blood sample for analysis. For these patients, therefore, peak peripheral CD34 þ cell counts occurred on day 1 of the cycle. Analysis of peak peripheral CD34 þ cell counts between the clinically relevant days 7 and 12 of the cycle showed values similar to the filgrastim group among patients in the 6 and 12 mg pegfilgrastim groups. In contrast, the peak peripheral CD34 þ cell count for the 18 mg pegfilgrastim group was statistically significantly higher than that in the filgrastim group (3.14 Â 10 4 /ml vs 1.19 Â 10 4 /ml; P ¼ 0.043; Table 3 ). Only one-third or fewer patients in any treatment group achieved a target peripheral CD34 þ cell count 44.0 Â 10 4 / ml during cycle 1. The proportions of those who achieved this target for more than two consecutive measurements were even less ( Table 3) . Proportions of patients who achieved the lesser target of 42.0 Â 10 4 CD34 þ cells/ml for more than two consecutive measurements were at similarly low levels, and there were no notable differences between treatment groups. However, greater numbers of patients in each treatment group achieved the lesser target of 42.0 Â 10 4 CD34 þ cells/ml at some time during cycle 1. The proportions of those receiving 12 or 18 mg doses of pegfilgrastim who did so (approximately 59%) were greater than the proportions of those receiving pegfilgrastim 6 mg or filgrastim who did so (approximately 28%; Table 3 ). The 95% confidence intervals, however, were broad and overlapped across treatment groups, making it impossible to draw firm conclusions.
Peripheral progenitor cell counts in cycles 0 and 1 Peripheral colony-forming unit (CFU) profiles over time in cycle 0 are shown in Figure 3 . The mean peak CFU counts þ cells in cycle 0 (prechemotherapy). Bars indicate 95% confidence intervals. The mean peak CD34 þ cell count was significantly higher in the pegfilgrastim 18 mg group compared with the filgrastim group (P ¼ 0.014). For days 3-7, the mean peak count for the 12 mg pegfilgrastim group was also significantly higher than that for the filgrastim group (P ¼ 0.034).
Pegfilgrastim mobilization of CD34
þ cells F Willis et al in each treatment group in cycles 0 and 1 are shown in Table 4 . The profiles indicate that the timing and extent of progenitor cell mobilization induced by each single dose of pegfilgrastim (6, 12 and 18 mg) were comparable with those observed in response to daily doses of filgrastim (10 mg/kg in cycle 0; 5 mg/kg in cycle 1) in both cycles 0 and 1. Mean peak CFU counts in the 6 mg pegfilgrastim treatment group were comparable with those observed in the filgrastim treatment group (Table 4) . In cycle 0, a positive doseresponse relationship was seen with increasing doses of pegfilgrastim, the mean peak CFU count in the 18 mg treatment group being approximately twice that in the filgrastim group (14 867 vs 7449 CFU/ml, respectively; Table 4 ). No clear dose-response relationship was apparent between the pegfilgrastim treatment groups in cycle 1.
Safety
Both pegfilgrastim and filgrastim were generally well tolerated. The adverse event profile was consistent with the nature of the underlying malignancies in the patient population undergoing chemotherapy. Overall, within cycle 0 (prechemotherapy), 32/61 (52%) patients reported one or more adverse events considered to have been related to the treatment. Consistent with the known safety profiles of filgrastim and pegfilgrastim, musculoskeletal events were the most common, being reported by 20 (33%) patients distributed approximately evenly throughout the treatment groups. All instances of treatment-related adverse events in this latter category were mild or moderate in severity, except in one patient who had severe bone pain.
Two deaths occurred. The first death occurred in cycle 0 in a patient who had previously reported three cytokinerelated serious adverse events (diarrhoea, cardiorespiratory arrest and hallucinations). The cause of death was recorded as hepatic metastases, which had been diagnosed before the first dose of pegfilgrastim (12 mg). Nevertheless, because the death was unexpected, and no other drug had recently been administered, it was judged that there was a reasonable possibility that the event was related to pegfilgrastim. The second patient died in cycle 1 as a result of intestinal perforation following corticosteroid use and also had neutropenic sepsis (death unrelated to pegfilgrastim 6 mg).
Discussion
Mobilization of human peripheral blood CD34
þ cells by pegfilgrastim has been shown using weight-based regimens of 30-300 mg/kg in normal volunteers and patients with non-small cell lung cancer, 7, 16 and more recently using 6 and 12 mg fixed-dose regimens in patients with lymphoma or myeloma. 17, 18 This study was designed to provide preliminary dose-finding information on the ability of fixed 6, 12 and 18 mg doses of pegfilgrastim to mobilize peripheral blood CD34 þ cells in patients with solid Abbreviations: CI ¼ confidence interval. Proportions are based on number of patients in each group starting cycle. a 10 mg/kg/day. b Analysis of variance using log (response) ¼ treatment.
Pegfilgrastim mobilization of CD34 þ cells F Willis et al tumours in comparison with daily doses of filgrastim. All doses were well tolerated and the safety profiles were as anticipated on the basis of past experience.
It was thought that the mobilization in cycle 0 would be sufficient, as the patients were chemotherapy-naive with no evidence of BM involvement. Mean peak peripheral CD34 þ cell counts 44.0 Â 10 4 /ml were achieved with daily filgrastim 10 mg/kg, whether assessed across the entire cycle or across only days 3-7, the clinically anticipated mobilization period. Similar mean peak peripheral CD34 þ cell counts were observed in the pegfilgrastim 6 mg group. Higher values were seen in the pegfilgrastim 12 and 18 mg groups. In both the pegfilgrastim 12 and 18 mg groups, the mean peak peripheral CD34 þ cell count during days 3-7 was statistically significantly higher than that in the filgrastim group. In addition, 93% of patients in each of the pegfilgrastim 12 and 18 mg groups achieved the target of 44.0 Â 10 4 /ml peripheral CD34 þ cells during the cycle. This was considered to be a suitable target to allow successful PBPC collections in a single apheresis procedure. The CFU mobilization profile was similar to that of CD34 þ cells in all groups; CFU counts generally increased with increasing dose of pegfilgrastim.
In cycle 1, pegfilgrastim and filgrastim (at the approved dose of 5 mg/kg) were administered 24 h after patients had received carboplatin/paclitaxel chemotherapy. The mean peak peripheral CD34 þ cell counts achieved were similar in all treatment groups, but were lower than expected from previously published results. For pegfilgrastim 18 mg, when assessment was made over cycle days 7-12, the period in which peak values postchemotherapy are clinically expected, there was a statistically significant increase in mean peak peripheral CD34 þ cell count compared with filgrastim. A minority of patients in each treatment group þ cell concentration in cycle 1 are unclear, but it may be that carboplatin/paclitaxel, a widely used therapeutic regimen for solid tumour patients, does not allow adequate PBPC mobilization. In an earlier study of similar design, 16 mobilization of peripheral CD34 þ cells in non-small cell lung cancer patients by filgrastim, and pegfilgrastim was not noticeably deficient postchemotherapy compared with prechemotherapy. Nevertheless, only a small number of patients (13 in all) were studied by Johnston et al. 16 and a considerable degree of interpatient variability was noted. Prior chemotherapy per se is unlikely to have been responsible, as Steidl et al. 18 have reported median peak peripheral CD34 þ cell counts of 7.8 Â 10 4 /ml in myeloma patients administered a 12 mg dose of pegfilgrastim following induction chemotherapy and CY. Similarly, in lymphoma patients, Isidorins et al. 17 have reported a median peak CD34 þ cells after ifosfamide, epirubicin and etoposide chemotherapy and pegfilgrastim 6 mg of 141 Â 10 6 /l. In this study, 24 of 25 patients achieved a target CD34 þ cell dose of 2.0 Â 10 6 /kg in a single apheresis procedure. Mobilization with both filgrastim and pegfilgrastim 6 or 12 mg has also been reported by Russell et al. 21 following ifosfamide, carboplatin and etoposide chemotherapy. What remains unclear is whether the 14-day interval between the first and second mobilization attempts was insufficient to allow haematopoietic potential to have been restored. The fact that 14/61 (23%) patients across all treatment groups had their peak CD34 þ counts on day 3 of cycle 1 (prenadir) suggests that, with the 14-day interval between cycles 0 and 1, patients did not return to their baseline CD34 þ counts and that this interfered with the expected CD34 þ profiles postchemotherapy. In addition, it may be that the cytokine milieu in patients with untreated, advanced stage, often bulky solid tumours, despite their having had no evidence of BM involvement, interfered with mobilization. It could also be hypothesized that the administration of pegfilgrastim in cycle 0 affected BM function in cycle 1 when chemotherapy was delivered. This seems unlikely, however, as studies in both healthy volunteers and cancer patients suggest that clinically relevant concentrations of pegfilgrastim are cleared within 12 days of administration. 22, 23 This study was intended to investigate the feasibility of PBPC mobilization with pegfilgrastim in patients with solid tumours. Extrapolation of these findings to cell harvest is therefore speculative. However, as similar peak CD34 þ cell levels were observed following mobilization with pegfilgrastim 6 mg and daily filgrastim, similar cell harvests during apheresis could be expected. Our data indicate that mobilization may increase with higher doses of pegfilgrastim, suggesting that fewer aphereses may be needed to obtain sufficient cells for transplant, but that this would need to be shown in further studies.
Overall, the results of this study support a single fixed dose of pegfilgrastim (6 mg or higher) as a substitute for daily doses of filgrastim for cytokine-alone peripheral CD34 þ mobilization. Although, in this study, the efficacy of pegfilgrastim for CD34 þ mobilization following chemotherapy was not clearly shown, several other studies have confirmed that this is an effective approach. Pegfilgrastim mobilization of CD34 þ cells F Willis et al
